InflaRx N.V. (NASDAQ:IFRX - Get Free Report) shares shot up 2.1% during mid-day trading on Wednesday . The company traded as high as $0.90 and last traded at $0.89. 215,162 shares changed hands during trading, a decline of 27% from the average session volume of 294,997 shares. The stock had previously closed at $0.88.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on IFRX. HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of InflaRx in a report on Friday, March 21st. Oppenheimer cut their price objective on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Guggenheim lifted their price objective on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, March 26th. Raymond James Financial cut InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price objective on the stock. in a report on Thursday, May 29th. Finally, Cantor Fitzgerald began coverage on InflaRx in a report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $6.60.
Read Our Latest Report on InflaRx
InflaRx Price Performance
The stock has a market capitalization of $60.42 million, a P/E ratio of -1.10 and a beta of 1.29. The company's 50-day simple moving average is $1.16 and its 200-day simple moving average is $1.55.
InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. On average, analysts forecast that InflaRx N.V. will post -1.04 earnings per share for the current fiscal year.
Institutional Trading of InflaRx
Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC bought a new position in InflaRx in the fourth quarter valued at about $28,000. Cubist Systematic Strategies LLC grew its stake in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after purchasing an additional 7,616 shares during the period. XTX Topco Ltd acquired a new stake in InflaRx in the first quarter valued at approximately $38,000. Walleye Capital LLC acquired a new stake in InflaRx in the fourth quarter valued at approximately $51,000. Finally, Geode Capital Management LLC grew its stake in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after acquiring an additional 11,900 shares during the period. 42.39% of the stock is currently owned by institutional investors.
InflaRx Company Profile
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
See Also
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.